Small Intestinal Bacterial Overgrowth (SIBO) is a condition characterized by excessive bacterial colonization of the small intestine (>10³ CFU/mL in proximal jejunum, >10⁵ CFU/mL in distal ileum), typically by colonic-type bacteria, resulting from impaired gastrointestinal motility, structural abnormalities, or immune dysfunction. This leads to malabsorption, fermentation-induced symptoms, and systemic inflammation through barrier damage and endotoxin translocation.
Think of the small intestine as a one-way street with street sweepers (the migrating motor complex) that come through every 90-120 minutes during fasting, pushing bacteria from the small bowel down into the colon where they belong. SIBO happens when the street sweepers stop running—maybe the city's diesel supply is low (hypothyroidism slowing everything), or the street's been blocked by construction (adhesions, strictures), or the police station shut down (immune deficiency). Without regular sweeping, bacteria from the colon migrate backward up the street and set up camp.
Now imagine these colonic bacteria are industrial fermenters that belong in the waste processing plant (colon), but they've moved into the food distribution warehouse (small intestine). They start fermenting the carbohydrates meant for absorption, producing gas (hydrogen, methane, hydrogen sulfide) that inflates the warehouse like a balloon. They also break apart the delivery labels on fat packages (deconjugate bile salts), causing fat to slip through unabsorbed, creating greasy stool. Some bacteria even eat the vitamin B12 meant for your body. Worst of all, their waste products damage the warehouse walls (intestinal barrier), allowing toxins to leak into the bloodstream—turning a local warehouse problem into a whole-body inflammation crisis.
Normal small intestine maintains bacterial counts <10³ CFU/mL through five integrated defense mechanisms:
Phase 1 - Barrier Breakdown:
Multiple mechanisms can disrupt normal defenses: (1) Reduced motility → hypothyroidism decreases thyroid hormone T3 → slowed GI transit → bacterial stasis; opioid medications bind mu opioid receptors → inhibit acetylcholine release → paralyze MMC; diabetic autonomic neuropathy damages enteric neurons → loss of MMC coordination; scleroderma fibrosis → intestinal smooth muscle dysfunction. (2) Structural problems → diverticula create bacterial reservoirs; strictures from Crohn's disease slow flow; surgical adhesions create blind loops; post-surgical anatomy (Billroth II, Roux-en-Y) disrupts normal flow. (3) Hypochlorhydria → PPI use raises gastric pH >4 → bacteria survive stomach acid; H. pylori-induced atrophic gastritis → reduced parietal cell H+-K+ ATPase → pH rises; aging reduces gastric acid production. (4) Reduced bile flow → cholestasis decreases bile salt concentration → loss of bacteriostatic effect. (5) Immune deficiency → IgA deficiency (1:600 prevalence) → loss of secretory IgA pathogen binding; HIV reduces CD4+ T cells → impaired immune surveillance.
Phase 2 - Bacterial Colonization:
When defenses fail, colonic-type bacteria (Escherichia coli, Enterococcus, Klebsiella, Streptococcus) colonize the small intestine. Three distinct SIBO variants emerge based on dominant organism metabolic capacity: (1) Hydrogen SIBO → bacteria ferment carbohydrates → produce H2 gas via hydrogenase enzymes → bloating, diarrhea-predominant. (2) Methane SIBO (IMO - Intestinal Methanogen Overgrowth) → Methanobrevibacter smithii (archaea, not bacteria) consumes H2 → produces CH4 methane → methane slows colonic transit via opioid-like effects on enteric neurons → constipation-predominant symptoms. (3) Hydrogen Sulfide SIBO → sulfate-reducing bacteria (Desulfovibrio) produce H2S → toxic to colonocytes at high concentrations → damages mitochondrial cytochrome c oxidase → diarrhea, sulfur smell to gas.
Phase 3 - Malabsorption Cascade:
Bacterial overgrowth disrupts nutrient absorption through multiple mechanisms: (1) Bile salt deconjugation → bacterial bile salt hydrolase (BSH) cleaves glycine/taurine from conjugated bile salts → unconjugated bile salts less efficient at micelle formation → fat malabsorption → steatorrhea → fat-soluble vitamin deficiency (A, D, E, K2). (2) Vitamin K2 specific pathway → normally gut bacteria produce menaquinone-7 (MK-7, long-chain vitamin K2) in colon, but SIBO bacteria in small intestine either don't produce it or consumption via deconjugated bile salts prevents absorption → undercarboxylated osteocalcin → impaired calcium binding to bone matrix → stress fractures despite adequate calcium intake. (3) B12 consumption → bacteria competitively bind B12 before intrinsic factor can facilitate ileal absorption → serum B12 <200 pg/mL → megaloblastic anemia → elevated homocysteine. (4) Brush border damage → bacterial products (proteases, lipopolysaccharide) damage microvilli → reduced lactase, sucrase, maltase expression on enterocyte surface → secondary lactose intolerance and carbohydrate malabsorption.
Phase 4 - Barrier Dysfunction and Systemic Effects:
Chronic SIBO creates intestinal barrier damage: bacterial lipopolysaccharide (LPS) binds TLR4 on enterocytes → NF-κB activation → inflammatory cytokine production (TNF-α, IL-1β, IL-6) → tight junction protein degradation (claudin-2 upregulation, occludin downregulation) → increased intestinal permeability. LPS and bacterial DNA fragments translocate across damaged barrier → bind TLR4 on Kupffer cells in liver and macrophages systemically → systemic inflammatory response → elevated CRP (>3 mg/L) → contributes to metabolic endotoxemia → insulin resistance via IRS-1 serine phosphorylation → creates vicious cycle as insulin resistance itself impairs gut motility through altered enteric neuron signaling.
Hypothyroidism-SIBO Vicious Cycle:
Low thyroid hormone (free T4 <0.8 ng/dL, TSH >2.5 mIU/L) → reduced mitochondrial oxidative phosphorylation in intestinal smooth muscle → decreased ATP availability for contraction → slowed MMC frequency (from every 90-120 min to >180 min) → bacterial overgrowth → endotoxemia → LPS activates type 2 deiodinase (DIO2) in hypothalamus → local T4→T3 conversion creates negative feedback → suppresses TRH release from paraventricular nucleus → further TSH suppression → worsening hypothyroidism → further gut dysmotility. Additionally, LPS increases type 3 deiodinase (DIO3) peripherally → converts T4 and T3 to inactive reverse T3 → functional hypothyroidism even with normal TSH.
SIBO is critically underdiagnosed in cPNI practice and explains symptom clusters that conventional medicine often fragments into separate diagnoses. The classic presentation—postprandial bloating (worse 1-2 hours after carbohydrate meals), alternating bowel habits, abdominal distension, flatulence—should trigger SIBO investigation, but systemic manifestations are equally important.
Nutrient Deficiency Patterns:
SIBO patients develop specific deficiency patterns that appear paradoxical with adequate dietary intake: (1) Vitamin K2 deficiency despite eating fermented foods or K2 supplements—bile salt deconjugation prevents absorption, and bacterial MK-7 production occurs in wrong location (small intestine instead of colon). This manifests as stress fractures in athletes or active individuals despite "good" bone density on DEXA scans—the problem is osteocalcin undercarboxylation, not mineral density. (2) B12 deficiency with normal intrinsic factor and no history of pernicious anemia—bacterial consumption depletes B12 before absorption. (3) Iron deficiency anemia that doesn't respond to oral supplementation—bacterial siderophores sequester iron, and chronic inflammation elevates hepcidin → blocks ferroportin → functional iron deficiency. (4) Fat-soluble vitamin deficiencies (low vitamin D <30 ng/mL despite supplementation, vitamin A deficiency with night blindness, vitamin E with peripheral neuropathy symptoms).
Metabolic and Endocrine Connections:
The SIBO-hypothyroidism bidirectional relationship creates clinical complexity: hypothyroidism is both cause and consequence of SIBO. A patient presenting with subclinical hypothyroidism (TSH 2.5-10 mIU/L, normal T4) and gastrointestinal symptoms should be evaluated for SIBO before initiating thyroid hormone replacement—treating SIBO may normalize thyroid function by removing inflammatory suppression of HPT axis. Conversely, patients with established hypothyroidism who develop new GI symptoms likely have SIBO from chronic dysmotility.
SIBO contributes to insulin resistance through chronic low-grade endotoxemia (LPS 50-200 pg/mL, compared to <50 pg/mL in healthy controls). This metabolic endotoxemia activates inflammatory pathways: LPS → TLR4 → IκB kinase activation → IκB phosphorylation → NF-κB nuclear translocation → inflammatory gene transcription including TNF-α and IL-6 → IRS-1 serine-307 phosphorylation → impaired insulin receptor signaling → compensatory hyperinsulinemia (fasting insulin >10 μIU/mL) → insulin resistance. This connects SIBO to metabolic syndrome, type 2 diabetes risk, and PCOS in women (insulin-driven ovarian androgen production).
Immune System Dysregulation:
Chronic antigen exposure from bacterial overgrowth creates immune exhaustion: continuous TLR4 stimulation → SOCS3 upregulation → suppressor of cytokine signaling dampens immune responses → paradoxical immune deficiency despite inflammation. Patients become susceptible to recurrent infections (respiratory, urinary tract) while simultaneously having elevated inflammatory markers (CRP 3-10 mg/L, ferritin >150 ng/mL in women, >200 ng/mL in men despite normal iron stores).
The intestinal barrier damage allows dietary protein fragments to cross into lamina propria before complete digestion → antigen presentation by dendritic cells → adaptive immune responses to food proteins → food sensitivities that weren't present before SIBO developed. This explains the common clinical scenario of a patient who "suddenly" becomes reactive to multiple foods—it's not new allergies, it's barrier dysfunction allowing immune system exposure to incompletely digested proteins.
Neurological and Psychological Manifestations:
SIBO-induced inflammation affects brain function through multiple pathways: (1) Vagal signaling → intestinal inflammation activates vagal afferents → nucleus tractus solitarius → hypothalamus → sickness behavior (fatigue, anhedonia, social withdrawal). (2) Kynurenine pathway activation → inflammatory cytokines (IFN-γ, TNF-α) induce indoleamine 2,3-dioxygenase (IDO) → tryptophan shunted to kynurenine rather than serotonin → reduced 5-HT synthesis → depression symptoms. (3) Brain fog → chronic inflammation increases blood-brain barrier permeability → inflammatory mediators enter CNS → microglial activation → neuroinflammation → impaired cognitive function, concentration difficulties.
Clinical Testing and Thresholds:
Breath testing remains standard diagnostic approach: after lactulose or glucose load, breath hydrogen >20 ppm above baseline within 90 minutes indicates SIBO (small intestine fermentation); methane >10 ppm at any point indicates IMO. Hydrogen sulfide SIBO requires specialized testing (trio-smart breath test measuring all three gases). Limitations: false negatives occur with recent antibiotic use, non-hydrogen-producing bacteria, rapid transit. Small intestinal aspirate culture (>10³ CFU/mL proximal jejunum) is gold standard but invasive and rarely performed in practice.
Secondary markers: elevated urinary indican (bacterial tryptophan metabolism), elevated serum D-lactate (bacterial fermentation product), low serum citrulline <20 μmol/L (marker of enterocyte damage and reduced small bowel mass).
Intervention Implications:
Treatment must address root cause, not just bacterial overgrowth: (1) Restore motility → if hypothyroidism, optimize thyroid replacement (aim TSH 0.5-2.0 mIU/L, free T3 in upper half of reference range); if medication-induced, consider alternatives to opioids or PPIs; prokinetics (low-dose erythromycin 50mg nightly as motilin agonist, or prucalopride 2mg daily as 5-HT4 agonist) can restore MMC function. (2) Antimicrobial phase → rifaximin 550mg TID for 14 days (non-absorbed antibiotic targeting small bowel) for hydrogen SIBO; add neomycin 500mg BID for methane-producers. Herbal antimicrobials (berberine 500mg TID, oregano oil, neem) show equivalent efficacy in studies. (3) Restore barrier → L-glutamine 5g TID supports enterocyte tight junction protein synthesis; zinc carnosine 75mg BID enhances mucosal healing; collagen peptides 10-20g daily provide glycine and proline for barrier repair. (4) Dietary modification → low-FODMAP diet during treatment reduces bacterial fermentation substrate, but should not be long-term due to potential negative effects on beneficial colonic microbiota. (5) Address nutrient deficiencies → methylcobalamin B12 1000-5000 mcg sublingual or IM injection; vitamin K2 MK-7 200 mcg daily with fat; iron bisglycinate 25-50mg with vitamin C if iron-deficient.
Evolutionary Mismatch Perspective:
SIBO represents collision between modern environment and evolved physiology: PPIs (used by 10-15% of Western populations) create hypochlorhydria that would never occur naturally; chronic stress suppresses vagal tone → impaired MMC; sedentary behavior reduces the mechanical effects of movement on gut motility; frequent eating (grazing pattern) prevents fasting MMC activation (MMC only occurs during fasting state). Hunter-gatherers with intermittent eating patterns (14-16 hour overnight fasts), high physical activity levels, and minimal exposure to acid-suppressing medications would rarely develop SIBO. The condition exemplifies how modern lifestyle disrupts integrated defense systems that evolved over millions of years.